Efficacy and safetyof etelcalcetide In patients receiving hemodialysis with hyperparathyroidism:Real life data
-
- Englisch ausgewählt
Fr. 39.90
inkl. gesetzl. MwSt.,
Beschreibung
Produktdetails
Einband
Taschenbuch
Erscheinungsdatum
06.11.2019
Verlag
LAP LAMBERT Academic PublishingSeitenzahl
68
Maße (L/B/H)
22/15/0.5 cm
Gewicht
119 g
Sprache
Englisch
ISBN
978-620-0-45764-6
Secondary hyperparathyroidism (sHPT) is common in hemodialysis (HD) patients. The present study aimed to evaluate the efficacy and safety profile of etelcalcetide, a new peptide calcium-sensing receptor (CaSR) agonist in an observational study for the treatment of sHPT in CKD patients on HD.60 HD stable patients with sHPT were received etelcalcetide for 10 months. PTH levels, Ca, Ph, alb were measured before starting etelcalcetide and every month until the end of the protocol. Heart function was also evaluated. The primary outcome was estimation of PTH concentrations at the end of the treatment period. Secondary outcomes were monitoring of corrected serum Ca, ph. Adverse events were also evaluated. PTH significantly decreased from the first month of the treatment with etelcalcetide until the end of the study period. We also noticed significant reduction of the ph levels even from the second month of treatment. This trend also carried out for 8 months. Heart function remained stable. Ca levels remained in accepted area. None of the patients dropped out due to adverse events.Etelcalcetide is safe, well tolerated and effective in reducing PTH in HD patients with sHPT.
Noch keine Bewertungen vorhanden
Verfassen Sie die erste Bewertung zu diesem Artikel
Helfen Sie anderen Kundinnen und Kunden durch Ihre Meinung.